Implementation of preemptive pharmacogenetic testing: progress, puzzles and priorities from an implementation science perspective
Rong Hu, Kaizhi Weng, Biyun Guo, Shuquan Zhuang, Junli Zhou, Zhiming Hong, Ping Lin, Chunping Wu, Zhiyuan Chen, Yue Wang, Xiaofang Wang, Huiyan Huang, Hui Zhang, Hao Zheng, Yingyi He · 2026
Read Implementation of preemptive pharmacogenetic testing: progress, puzzles and priorities from an implementation science perspective by Rong Hu, Kaizhi Weng, Biyun Guo, Shuquan Zhuang, Junli Zhou, Zhiming Hong, Ping Lin, Chunping Wu, Zhiyuan Chen, Yue Wang, Xiaofang Wang, Huiyan Huang, Hui Zhang, Hao Zheng, Yingyi He (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13613977.txt.
Description
Hu and colleagues review why gene tests that guide drug choice are still rare in daily care, in a paper from twenty twenty-six. These tests check a person's genes before a drug is given. They can warn if a drug may harm the person or fail to help. The review looks at ten years of work to bring the tests into clinics.
Use of the tests is now well tracked, but proof that clinics keep them up is thin. Most cost claims come from models, not real trials. The team calls for clear work steps, staff training, and shared tools. They also note that almost all past work comes from rich states, so poor states need plans that fit their own needs.
Catalog record
| CREATOR | Rong Hu, Kaizhi Weng, Biyun Guo, Shuquan Zhuang, Junli Zhou, Zhiming Hong, Ping Lin, Chunping Wu, Zhiyuan Chen, Yue Wang, Xiaofang Wang, Huiyan Huang, Hui Zhang, Hao Zheng, Yingyi He |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |